dc.creatorThome-Souza, Sigride
dc.creatorMoreira, Bernardo
dc.creatorValente, Kette D.
dc.date.accessioned2013-09-26T13:54:06Z
dc.date.accessioned2018-07-04T15:57:03Z
dc.date.available2013-09-26T13:54:06Z
dc.date.available2018-07-04T15:57:03Z
dc.date.created2013-09-26T13:54:06Z
dc.date.issued2012
dc.identifierPEDIATRIC NEUROLOGY, NEW YORK, v. 47, n. 1, pp. 47-50, JUL, 2012
dc.identifier0887-8994
dc.identifierhttp://www.producao.usp.br/handle/BDPI/33753
dc.identifier10.1016/j.pediatrneurol.2012.04.026
dc.identifierhttp://dx.doi.org/10.1016/j.pediatrneurol.2012.04.026
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1629601
dc.description.abstractIndividuals treated with combined valproate-lamotrigine rarely present late adverse effects (unrelated to introduction and titration). We describe four patients in whom such effects occurred after continuous, long-term use of valproate-lamotrigine (at 9 months to 2 years after final antiepileptic drug adjustment). The patients presented heterogeneous disturbances, including ataxia, vertigo, and headache, and rare movement disorders, such as tics and abnormal eye movements. Although these effects are heterogeneous in their occurrence and timing, they can alert physicians to the possibility of late neurologic disturbances, and must be considered in order to avoid unnecessary ancillary tests. Treatment discontinuation is unnecessary, given that a small decrease in dose led to remission of these adverse effects. (c) 2012 Elsevier Inc. All rights reserved.
dc.languageeng
dc.publisherELSEVIER SCIENCE INC
dc.publisherNEW YORK
dc.relationPEDIATRIC NEUROLOGY
dc.rightsCopyright ELSEVIER SCIENCE INC
dc.rightsclosedAccess
dc.titleLate Adverse Effects of the Coadministration of Valproate and Lamotrigine
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución